Garry Nicholson
Chairman at G1 THERAPEUTICS, INC.
Net worth: 18 960 $ as of 2024-03-30
Profile
Mr. Garry A.
Nicholson is a Chairman at Day One Biopharmaceuticals, Inc. and a Chairman at G1 Therapeutics, Inc. He is on the Board of Directors at Tmunity Therapeutics, Inc. and XTuit Pharmaceuticals, Inc. Mr. Nicholson was previously employed as an Independent Director by NextCure, Inc., an Independent Director by Turning Point Therapeutics, Inc., an Independent Director by Personal Genome Diagnostics, Inc., an Independent Director by Five Prime Therapeutics, Inc., and a President-Pfizer Oncology by Pfizer Inc. He also served on the board at SQZ Biotechnologies Co., Tesaro, Inc. and The Pfizer Foundation, Inc. He received his undergraduate degree from The University of North Carolina at Chapel Hill and an MBA from the University of South Carolina.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
G1 THERAPEUTICS, INC.
0.01% | 2023-06-14 | 4,389 ( 0.01% ) | 18 960 $ | 2024-03-30 |
NEXTCURE, INC.
-.--% | 2023-06-21 | 0 ( -.--% ) | - $ | 2024-03-30 |
| 2024-03-14 | 0 ( -.--% ) | - $ | 2024-03-30 |
Garry Nicholson active positions
| Companies | Position | Start |
|---|---|---|
| G1 THERAPEUTICS, INC. | Chairman | 2019-06-11 |
| DAY ONE BIOPHARMACEUTICALS, INC. | Chairman | 2022-09-11 |
XTuit Pharmaceuticals, Inc.
 XTuit Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology XTuit Pharmaceuticals, Inc. develops drugs for the treatment of cancer. The firm develops pharmaceutical products for use in the diagnosis and treatment of oncological, tumor and inflammatory diseases. The company was founded by Alan L. Crane, Rakesh Kumar Jain, Andrew Werk Cook, Edwin L. Steele, David H. Koch, Ronald Evans, Howard Hughes and Robert S. Langer, Jr. in 2011 and is headquartered in Waltham, MA. | Director/Board Member | - |
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Director/Board Member | 2019-02-13 |
Former positions of Garry Nicholson
| Companies | Position | End |
|---|---|---|
| NEXTCURE, INC. | Director/Board Member | 2023-08-14 |
| TURG POIN | Chairman | 2021-05-23 |
| FIVE PRIME THERAPEUTICS, INC. | Director/Board Member | 2021-04-15 |
| PFIZER, INC. | Corporate Officer/Principal | 2015-03-30 |
Personal Genome Diagnostics, Inc.
 Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Director/Board Member | - |
Training of Garry Nicholson
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
| University of South Carolina | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| PFIZER, INC. | Health Technology |
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| G1 THERAPEUTICS, INC. | Health Technology |
| NEXTCURE, INC. | Health Technology |
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Personal Genome Diagnostics, Inc.
Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
The Pfizer Foundation, Inc.
 The Pfizer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., The Pfizer Foundation, Inc. is a company committed to transparency and disclosure of activities of public interest. The company is based in New York, NY. Pfizer is dedicated to discovering breakthrough treatments, including medicines and vaccines, to benefit patients worldwide. The company is focused on treating 225 million people with these breakthrough treatments by 2025. The company's areas of interest include funding for educational activities, health education, and scientific research. Additionally, Pfizer is exploring the potential of mRNA technology to fight viruses and is working to understand the differences between biologics and biosimilars, particularly in terms of cost. | Commercial Services |
XTuit Pharmaceuticals, Inc.
XTuit Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology XTuit Pharmaceuticals, Inc. develops drugs for the treatment of cancer. The firm develops pharmaceutical products for use in the diagnosis and treatment of oncological, tumor and inflammatory diseases. The company was founded by Alan L. Crane, Rakesh Kumar Jain, Andrew Werk Cook, Edwin L. Steele, David H. Koch, Ronald Evans, Howard Hughes and Robert S. Langer, Jr. in 2011 and is headquartered in Waltham, MA. | Health Technology |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Commercial Services |
- Stock Market
- Insiders
- Garry Nicholson
